Reprocell Co. acquires development and sales rights in Japan for Stemchymal, a cell product for the treatment of Polyglutamine Spinocerebellar Ataxia (PolyQ SCAs)

The cellular drug was developed by Taiwan’s Steminent Biotherapeutics Co. and is derived from adipose cells. Clinical trials in Japan will begin in autumn 2017.

Nikkei Biotech news release, November 15, 2016

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny